[Pharmacokinetics of amodiaquine and prevention of Plasmodium falciparum malaria].
Amodiaquine might appear as an alternative in prophylaxis of chloroquine-resistant P. falciparum malaria. In an attempt to explain the discrepancy between its in vivo-in vitro activity, a pharmacokinetic study was conducted in healthy subjects with HPLC assays. The results showed that: amodiaquine was no more detected in the blood, a main metabolite (monodesethyl derivative) appeared as the active form of the drug in vivo, metabolite's half-life had a mean value of 15.6 +/- 5.4 days. This study shows that monodesethylamodiaquine (and not amodiaquine) must be monitored in vitro. Furthermore the high individual variations of blood levels and half-life's values suggest that the weekly prophylactic schedule must be eventually re-evaluated.
D000328:Adult; D000655:Amodiaquine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood*; D005260:Female; D006207:Half-Life; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum
D000655:Amodiaquine; C047386:desethylamodiaquine
Pharmacocinétique de l'amodiaquine et prophylaxie du paludisme à Plasmodium falciparum.